Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure
Kidney Diseases, Congestive Heart Failure, Cardiomyopathy
About this trial
This is an interventional treatment trial for Kidney Diseases focused on measuring Heart failure, Renal dysfunction
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of class III-IV CHF requiring hospitalization for treatment of CHF. Mild - moderate renal insufficiency (20< Creatinine Clearance < 60 ml/min as calculated by the Cockcroft-Gault formula) Systolic BP > 90 Stable cardiac rhythm Unlikely to require cardiac catheterization Exclusion Criteria: Inability to give informed consent New onset atrial fibrillation with rapid ventricular response (HR >110 bpm) Active ischemia Known or suspected stenotic valve disease Acute clinical need for intravenous vasodilator (including BNP) therapy (Severely symptomatic despite rest, oxygen, initial standard therapy) Primary reason for admission other than treatment of decompensated CHF (rhythm, device, other medical problem)
Sites / Locations
- Mayo Clinic